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ABSTRACT Fibromuscular dysplasia (FMD) is a rare,
nonatherosclerotic arterial disease for which the molec-
ular basis is unknown. We comprehensively studied 47
subjects with FMD, including physical examination,
spine magnetic resonance imaging, bone densitometry,
and brain magnetic resonance angiography. Inflamma-
tory biomarkers in plasma and transforming growth
factor  (TGF-) cytokines in patient-derived dermal
fibroblasts were measured by ELISA. Arterial pathology
other than medial fibrodysplasia with multifocal steno-
sis included cerebral aneurysm, found in 12.8% of
subjects. Extra-arterial pathology included low bone
density (P<0.001); early onset degenerative spine dis-
ease (95.7%); increased incidence of Chiari I malfor-
mation (6.4%) and dural ectasia (42.6%); and physical
examination findings of a mild connective tissue dys-
plasia (95.7%). Screening for mutations causing known
genetically mediated arteriopathies was unrevealing.
We found elevated plasma TGF-1 (P0.009), TGF-2
(P0.004) and additional inflammatory markers, and
increased TGF-1 (P0.0009) and TGF-2 (P0.0001)
secretion in dermal fibroblast cell lines from subjects
with FMD compared to age- and gender-matched con-
trols. Detailed phenotyping of patients with FMD al-
lowed us to demonstrate that FMD is a systemic disease
with alterations in common with the spectrum of ge-
netic syndromes that involve altered TGF- signaling
and offers TGF- as a marker of FMD.—Ganesh, S. K.,
Morissette, R., Xu, Z., Schoenhoff, F., Griswold,
B. F., Yang, J., Tong, L., Yang, M.-L., Hunker, K.,
Sloper, L., Kuo, S., Raza, R., Milewicz, D. M., Fran-
comano, C. A., Dietz, H. C., Van Eyk, J., McDonnell,
N. B. Clinical and biochemical profiles suggest fibro-
muscular dysplasia is a systemic disease with altered
TGF- expression and connective tissue features.
FASEB J. 28, 3313–3324 (2014). www.fasebj.org
Key Words: biomarker  FMD  TGF-  pathway aneurysm
 human genetics
Fibromuscular dysplasia (FMD) is a rare, nonath-
erosclerotic vascular disease, originally described in
1938 (1), characterized by arterial dysplasia and ob-
struction to arterial blood flow by neointimal lesions
rich with cells with a smooth muscle phenotype (2). It
most commonly affects the renal arteries (presenting as
hypertension) and internal carotid arteries (presenting
as stroke or transient ischemic attack) but has been
described in virtually all arterial beds. Hyperplasia of
the intimal, medial, or adventitial layers of the arterial
wall leads to distinct FMD forms (3). Medial fibroplasia
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FMD accounts for 85% of cases, (3, 4) and is diag-
nosed on imaging due to a characteristic “string of
beads” appearance of alternating arterial stenosis and
aneurysmal dilation (Fig. 1).
Virtually no new information on FMD pertaining to
mechanisms of disease has been published in the last 4
decades (5). Currently there is no medical therapy
aimed at preventing progression or treating the under-
lying vascular pathology. Furthermore, there are no
biomarkers or defined clinical features to identify who
is at risk or who has the disorder. The current hypoth-
esis of the pathophysiology of FMD is that mechanical
factors or local trauma incite aberrant vascular remod-
eling in genetically predisposed individuals. Histo-
pathologic studies show that medial fibroplasia-type
FMD demonstrates lesions comprised of smooth mus-
cle cell hyperplasia in the narrowed portions of arteries,
haphazard fibroblast organization, and accumulation
of compact fibrous collagen (6, 7). A paucity of inflam-
matory cells has been noted in FMD lesions, although
whether the arterial remodeling is a sequelae of long-
term inflammation or excess cytokine expression as
seen in other fibrotic diseases is unknown (6, 8). Both
sporadic and familial cases have been reported. Lim-
ited pedigree studies show an autosomal dominant
inheritance pattern with incomplete penetrance and
variable expression (9). Lesions with similar radiologi-
cal appearance have been noted in genetically medi-
ated syndromes; however, no causative genes for FMD
have been identified to date (10–13).
We undertook a deep phenotyping study of 47
individuals with FMD to evaluate relevant genetic,
clinical, and anatomic features of this vascular disease.
MATERIALS AND METHODS
Study subjects
Individuals with a primary clinical diagnosis of FMD made at
an outside clinical center and who contacted the U.S. Na-
tional Institutes of Health, National Institute on Aging (NIH/
NIA) study center were enrolled and included in the current
analysis on confirmation of the presence of medial fibropla-
sia-type FMD as demonstrated by arterial beading or multifo-
cal stenosis (14, 15) on an outside angiographic imaging
Figure 1. FMD angiographic phenotype and histopathology. A, B, D, E) Each subject in the study had a clinical FMD diagnosis
on the basis of invasive or noninvasive angiography. Representative images from 4 subjects are shown with classic FMD changes
consistent with medial fibroplasia. A, B) Bilateral renal disease is shown in two different subjects. C) Histopathology shows
fibrous dysplasia of the excised segment of the renal artery from the subject in panel B, with elastin stained black, at 4 view.
D, E) Carotid artery FMD is shown, with multifocal stenosis seen in both images, but one focus of disease in panel D and two
regions of disease in panel E.
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study (conventional angiogram, computerized tomography,
or magnetic resonance angiography) done as part of each
subject’s routine clinical care prior to enrollment in the
study. The study protocol was approved by the MedStar
Health and NIA (protocol 2003-086) Institutional Review
Board. Each subject provided informed consent. Study par-
ticipants were enrolled between 2005 and 2012 and under-
went a comprehensive history and physical examination, full
spine MRI, and a bone densitometry scan. Skin biopsies were
performed on patients with FMD and submitted to the Coriell
Repository (Camden, NJ, USA; http://ccr.coriell.org) to de-
rive individual dermal fibroblast cell lines. Deidentified ap-
parently healthy dermal fibroblasts were obtained from the
Coriell repository (http://ccr.coriell.org). Age- and gender-
matched healthy controls for plasma analysis and bone den-
sitometry were obtained from the Baltimore Longitudinal
Study of Aging (BLSA), a community-based longitudinal
study with 50 yr of follow-up (16). Control subjects for all
analyses were matched to FMD case subjects for age (within 5
yr) and gender. Dermal fibroblast derivation methods and
cell culture passage number were equivalent in the FMD case
subject and control samples, and fibroblasts were analyzed at
the same passage number. Plasma samples from individuals
with Marfan syndrome (MFS) were obtained through the
same NIH protocol (2003-086) and analyzed as an additional
comparison group.
Clinical examination
A physical examination was performed by a clinical geneticist
(N.B.M.) and included auscultation for arterial bruits, skin
examination, and objective joint hypermobility measures
using the Beighton scale with the following maneuvers:
passive dorsiflexion of the little fingers beyond 90°, 1 point
for each hand; passive apposition of the thumbs to the flexor
aspect of the forearm, 1 point for each hand; hyperextension
of the elbows beyond 10°, 1 point for each elbow; hyperex-
tension of the knees beyond 10°, 1 point for each knee; and
forward flexion of the trunk with knees fully extended so the
palms of the hand rest flat on the floor, 1 point. Other clinical
features of hereditary connective tissue disorders were as-
sessed utilizing established clinical criteria for cardinal fea-
tures of each disorder. Medical and family history was noted
for each subject.
Spine MRI
MRI studies were completed on an Intera Philips 1.5 T
magnet with software version 11.1.4.4 (Philips, Amsterdam,
The Netherlands). All images were read by a single clinical
radiologist (R.R.) in a blinded procedure. In the spine MRI
interpretation, we utilized the narrow, but widely accepted,
definition of Chiari I malformation as tonsillar herniation of
5 mm below the foramen magnum (17). Tonsillar ectopia
was defined as tonsillar descent of 0 to 4 mm below the
foramen magnum.
Bone densitometry scanning
Dual-energy X-ray absorptiometry (DEXA) studies on FMD
case subjects and BLSA controls were performed on a GE
Lunar Prodigy Advance scanner (GE Healthcare, Piscataway,
NJ, USA) at the same location for all individuals. Population-
specific z scores were calculated similarly for FMD case
subjects and healthy controls.
Magnetic resonance angiography (MRA)
Vascular anatomy was assessed in each subject able to undergo a
study MRA on enrollment at the NIA clinical center with
gadolinium contrast (i.e., no renal dysfunction or other contra-
indications) from the brain through the pelvis by MRA images of
the entire arterial tree. MR studies were completed on an Intera
Philips 1.5 T magnet with software version 11.1.4.4. All images
were read by the same clinical radiologist experienced in arterial
disease determination, particularly artifacts that may appear as
beading (R.R.), and were also reviewed by the principal investi-
gator of clinical protocol 2003-086 (N.B.M.). Characteristics
defined in each artery included the presence of stenosis, defined
as 20% or greater luminal loss compared to the proximal
reference diameter in arteries sufficiently large to visualize
changes due to the special resolution of MRA (approximate
artery diameter typically 5 mm); aneurysm, defined as 50%
increase from the reference diameter immediately proximal or
distal to the involved segment, and smaller changes were called
ectatic; dissection, as evidenced by the presence of an intimal
flap; beading, defined as sequential stenosis with or without
aneurysmal dilation between stenotic segments; and arterial
tortuosity, coded when it appeared in arteries normally expected
to follow a straight course in otherwise healthy individuals.
Other vascular abnormalities, including anatomic variants and
atherosclerotic changes, were noted. Hypoplastic or absent
segments or arteries were categorized as arteries not well visual-
ized by MRA. Previously stented or bypassed arteries were coded
as not visualized.
Fibroblast cell culture
Dermal fibroblasts were cultured from a 4 mm punch skin
biopsy (18). Fibroblasts between passages 4 and 10 from case
subjects and age- and sex-matched controls were cultured to
confluence in high-glucose Dulbecco’s modified Eagle’s me-
dium, 10.0% fetal bovine serum, penicillin, and streptomycin
(Invitrogen, Carlsbad, CA, USA) at 37°C in 5.0% CO2. FMD
fibroblasts appeared morphologically similar to control fibro-
blasts. For Western blot experiments, untreated cells (for
pERK1/2 and p-p38) were grown to confluence before lysis.
Treated cells were grown to 80% confluence and then
serum starved for 18 h. Cells were then treated for 1 h with
either 10 ng/ml transforming growth factor 1 (TGF-1) or
TGF-2 (for pSmad2) or 50 ng/ml BMP-4 (for pSmad1/5/8)
(R&D Systems, Minneapolis, MN, USA) before lysis.
Enzyme-linked immunosorbent assays (ELISAs) for protein
marker measurement
Background TGF- found in fetal bovine serum was elimi-
nated by a series of washes and the addition of serum-free
medium for secretion experiments. Total TGF-1 and
TGF-2 concentrations in secreted medium from skin fibro-
blasts and total TGF-2 in platelet-poor EDTA-plasma were
measured by ELISA with the human TGF-1 and TGF-2
Quantikine ELISA kits (R&D Systems); samples were acid
activated according to the manufacturer’s instructions. Total
TGF-1, MCP-1, TNF-, CRP, SAA, ICAM-1, VCAM-1, and
IL-8 in human plasma were measured using a ruthenium-
based commercially available electrochemiluminescence plat-
form to measure systemic inflammation, according to the
manufacturer’s instructions (Meso Scale Discovery, Gaithers-
burg, MD, USA). Secreted IL-8 was measured using a human
CXCL8/IL-8 Quantikine ELISA kit (R&D Systems). Samples
used for TGF-1 were acid activated prior to assaying. All
samples were assayed in duplicate. The percentage coefficient
of variance was below 20% and above the lower level of
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quantification for each analyte. Secretion data were normal-
ized to protein concentration. Secretion of total TGF-1 and
TGF-2 from human skin fibroblasts was measured in a subset
of subjects with FMD and healthy subjects who provided
dermal biopsy samples and whose cell lines provided ade-
quate in vitro cell growth. The plasma TGF-2 was measured
at the same time as the secreted TGF-2 in the same subset of
patients so the results could be directly compared.
Cell cycle analysis
Cell cycle analysis was performed on dermal fibroblasts at80%
confluence using methods for propidium iodide (PI) and FACS
analysis (19). Cells were grown in culture to 90–95% conflu-
ence, harvested, washed, and suspended in 1 PBS, fixed in
ice-cold 70% ethanol, pelleted, and suspended in 500 l PI stain
(50 g/ml PI and 200 g/ml RNase A) for 60 min in the dark.
Samples were assayed by flow cytometry using FACSCalibur (BD
Biosciences, San Jose, CA, USA), and the raw data were analyzed
using the Modfit LT program (BD Biosciences). Bromodeoxyu-
ridine (BrdU) assays were performed in parallel as a second
method to assess cellular proliferation. Dermal fibroblasts were
seeded in a 96-well plate (5000 cells/well). After 18 h, BrdU was
added to cells in triplicate according to the BrdU Cell Prolifer-
ation Assay instructions (EMD Millipore, Billerica, MA, USA).
The BrdU incorporated for 6 h, and then the plate was pro-
cessed according to the manufacturer’s instructions. Values were
collected on a VersaMax microplate reader (Molecular Devices,
Sunnyvale, CA, USA). Triplicate values were averaged and then
subtracted from values from cells not treated with BrdU.
Western blot analysis
Protein expression was analyzed by SDS-PAGE electropho-
resis and Western blot. Fibroblasts were lysed with RIPA
buffer (Pierce, Rockford, IL, USA) containing protease
and phosphatase inhibitors (cocktail sets I–III; Calbio-
chem, Gibbstown, NJ, USA). Protein (30 g, as determined
by a BCA protein assay of whole-cell protein extracts and
using BSA as a standard; Pierce) was loaded onto a 4–20%
Novex Tris-Glycine precast gel (Invitrogen). Proteins were
then electrotransferred onto a PVDF membrane using Invit-
rogen’s iBlot dry blotting system, and immunoblotting was
done using the appropriate human antibodies. Specifically,
rabbit polyclonal anti-phospho-Smad1/5/8 (1:500; Cell Sig-
naling Technology, Danvers, MA, USA), anti-Smad1 (1:500,
Cell Signaling Technology), anti-phospho-Smad2 (1:500; Mil-
lipore, Billerica, MA, USA), anti-phospho-Erk1/2 (1:1000;
Cell Signaling Technology), anti-p38 MAPK (1:500; Cell
Signaling Technology), anti--tubulin (1:2000; Cell Signaling
Technology) or rabbit monoclonal anti-Smad2 (1:500; Cell
Signaling Technology), anti-Erk1/2 (1:1000; Cell Signaling
Technology), anti-phospho-p38 MAPK (1:500; Cell Signaling
Technology), and anti--actin (1:1000; Cell Signaling Tech-
nology) were used overnight at 4°C, followed by 1 h incuba-
tion with a secondary donkey anti-rabbit IgG ECL-HRP linked
antibody (1:5000; GE Healthcare, Piscataway, NJ, USA). Im-
munoreactive products were visualized by chemilumines-
cence using the ECL Plus kit (GE Healthcare). Quantification
of immunoblots was performed using ImageJ software (NIH,
Bethesda, MD, USA).
Genetic mutation analysis
DNA fragments covering coding regions and flanking se-
quences of genes of interest were amplified and then se-
quenced using the Big Dye Terminator V3.1 on the ABI
Genetic Analyzer 3130xl (Applied Biosystems, Foster City, CA,
USA). Alignment was performed with Sequencher 4.10.1
(Gene Codes Corp., Ann Arbor, MI, USA). Genes sequenced
are shown in Supplemental Tables S1 and S2, respectively.
Statistical analysis
Analyses were carried out using SAS 9.3 statistical software
(SAS Institute, Cary, NC, USA) and Microsoft Excel 2007
(Microsoft, Redmond, WA, USA); t tests were used to com-
pare DEXA measurements between case and control subjects
who were matched at a 1:3 ratio by age (5 yr) and gender.
Group comparisons for biomarkers were made with the inde-
pendent, 2-tailed sample t test, with statistical significance de-
fined as P  0.05, and represented as means  sem. Based on
the MRA data, an arterial disease severity score was constructed
by counting the number of arterial beds with beading, aneu-
rysm, stenosis, dissection or tortuosity in carotid, vertebral,
cerebral, mesenteric, iliac, and upper extremity arteries, and the
aorta. A second score was constructed counting beading only in
each arterial bed. Multivariable regression was performed on the
resulting score. Variable selection was applied by a stepwise
regression method using the adjusted R2 as the criterion to
determine which variables to include as predictors in the model.
In our initial model, severity score was the dependent variable,
and TGF- results, exogenous hormone usage, MRA findings,
age, and gender were included as independent variables. After
variable selection, the final model had the maximum adjusted
R2, which can be seen as a fraction index of the variance
explained by the model.
RESULTS
FMD patient population
In our study of 47 FMD case subjects, every subject with
FMD had received an outside angiographic diagnosis of
FMD in the clinical setting, and each subject showing
classic string-of-beads-type changes consistent with me-
dial fibrodysplasia, as confirmed by the study team, was
included in the cohort (Fig. 1). As part of their clinical
care prior to study enrollment, approximately half
(51.1%) of the study subjects had invasive treatment
(percutaneous or surgical) for the lesions in the pre-
senting arterial bed (Table 1).
Family history
Self-reported vascular diagnoses in first- and second-de-
gree family members were tallied for each FMD case
subject (Table 2). None of our FMD case subjects were
related to one another. In our study there were no
subjects with known connective tissue diseases, and there
were no family members with Ehlers-Danlos syndrome
(EDS), which has been reported in families of FMD
patients elsewhere (20, 21). Aneurysm was reported in 15
(31.9%) families, and specifically abdominal aortic aneu-
rysm was reported in 8 families (17.0%). Arterial dissec-
tion was uncommon and reported in only 1 family mem-
ber. Stroke was relatively common and seen in 28 (59.6%)
families.
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TABLE 1. Demographics, medical history, symptoms, and physical examination
Parameter Range Mean  sd N %
Demographics
Gender, female 43 91.5
Ethnicity, European ancestry 46 97.9
Medical history
Hypertension 31 66.0
Stroke or transient ischemic attack 23 48.9
Percutaneous coronary intervention for FMD 24 51.1
Surgery for FMD 10 21.3
Renal failure 1 2.1
Menopause 31 66.0
Hysterectomy 13 27.7
Venous thrombosis 0 0
Hyperlipidemia 21 44.7
Myocardial infarction 3 6.4
Osteoporosis 4 8.5
Age at study evaluation 19–67 51.0  9.0
Age at FMD presentation 16–65 44.5  12.8
Age of hypertension diagnosis 16–56 36.5  13.3
Age at stroke or transient ischemic attack 32–58 47.2  8.1
Age at percutaneous coronary intervention for FMD 16–58 45.7  11.2
Age at surgery for FMD 16–56 40.9  13.6
Age at menopause 28–54 45.2  7.8
Myopia 28 59.6
Retinal detachment 9 19.1
Raynaud’s phenomenon 11 23.4
Livedo reticularis 14 29.8
Symptom and activity history
Competitive sports 4 8.5
Runner, competitive or noncompetitive 5 10.6
Miles running per week  15 3 6.4
Days running per week  4 4 8.5
Swooshing sound in ears 17 36.2
Headache 25 53.2
Claudication 1 2.1
Neck pain 32 68.1
Back pain 32 68.1
Abdominal pain 12 25.5
Flank pain 1 2.1
Dizziness 13 27.7
Tinnitus 12 25.5
Neurologic deficit 14 29.8
Joint pain 32 68.1
Medication history
Angiotensin receptor blocker, at study evaluation 10 21.3
Angiotensin receptor blocker, ever 11 23.4
Oral contraceptive pills, at study evaluation 2 4.3
Oral contraceptive pills, current or former use 18 38.3
Hormone replacement therapy, at study evaluation 13 27.7
Hormone replacement therapy, current or former use 16 34.0
Any history of exogenous estrogen use 29 61.7
Anxiolytic or antidepressant, at study evaluation 19 40.4
Narcotic use, at study evaluation 6 12.8
Tobacco and alcohol use
Current or former smoker 18 38.3
Alcohol consumption  7 drinks/wk 7 14.9
Physical examination
Height (cm) 149.4–181.0 165.9  6.8
Weight (kg) 48.4–100.4 70.2  12.1
Body surface area 1.5–2.1 1.8  0.1
Body mass index 19.5–35.7 25.5  3.6
Systolic blood pressure 96–159 129.0  14.7
Diastolic blood pressure 54–90 70.2  9.7
Pulse 46–91 65.6  10.1
Beighton score  5 27 57.4
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Genetic analysis
Based on established clinical criteria for genetic testing
for various gene mutations, subjects meeting the corre-
sponding criteria underwent molecular genetic screen-
ing for mutations in COL3A1, FBN1, PLOD1, TGFBR1,
TGFBR2, TGFB2, SMAD3, ACTA2, and COL5A1. The
selection criteria are outlined in Supplemental Table
S1. No pathogenic mutations were identified.
Clinical features
Of the 47 subjects, 43 were female (91.5%) with a
median age at FMD presentation of 50 yr (mean 44.5
yr) and median age at study enrollment of 53 yr (mean
51.0 yr) (Table 1); 48.9% had a history of stroke or
transient ischemic attack (TIA), 53.2% had chronic
headache, and 66.0% had a history of hypertension.
History of exogenous estrogen use of any kind was
noted in 61.7%; similar to prior reports, parity rates
and pregnancy complications were not elevated above
population estimates (6). Current or former smoking
history was present in 38.3%.
On MRI of the spine, despite the relatively young age
of our cohort, 95.7% showed degenerative disc disease,
and 74.5% showed degenerative facet changes at any
location (Table 3 and refs. 22, 23). Spinal stenosis was
noted in 66.0% of subjects. Surprisingly, a high inci-
dence of Chiari I malformation (6.4%) and tonsillar
ectopia (14.9%) was seen on cervical spine MRI, and
42.6% of the subjects had evidence of dural ectasia.
Scoliosis was severe enough to be noted by MRI in
29.8% of subjects (Table 3), which was lower than the
estimate of 78.7% by clinical examination in the setting
of weight bearing in a patient with joint laxity (Table 1
and refs. 1, 2). On DEXA scans, we found a loss of bone
density on examination of the femoral neck (P	0.001),
with adjustment for age, gender, and BMI. We did not
analyze spinal bone density due to extensive degener-
ative disease seen on MRI in our subjects. On physical
examination, FMD subjects demonstrated significant
musculoskeletal features. By clinical examination, a
Beighton score 5 was found on examination in 57.4%
of our subjects (Table 1), which is a rare finding in this
age group in the Caucasian population (24, 25). Hip
laxity, as evidenced by the ability to place the foot over
the head in a seated position, was seen in 83.0% of our
subjects. Additional features specifically interrogated,
which have been associated with other forms of hered-
itary disorders of connective tissue, included small joint
hyperextension, (n
38, 80.9%), pes planus (n
34,
72.3%), hammertoes (n
9, 19.1%), hypertelorism
(n
10, 21.3%), any abnormality of uvula (n
7,
14.9%), dolichocephaly (n
5, 10.6%), malar hypopla-
sia (n
17, 36.2%), palate abnormality (high palate or
palate torus; n
41, 87.2%), blue-tinged sclera (n
30,
63.8%), pectus deformity of any kind (n
19, 40.4%),
downsloping ribs (n
12, 25.5%), velvety skin (n
25,
53.2%), stretchy skin (n
27, 57.4%), abnormal scars
(n
27, 57.4%), piezogenic papules (n
30, 63.8%),
scoliosis on examination, which includes functional
scoliosis in the setting of excessive joint laxity in some
of the subjects (n
37, 78.7%), arachnodactyly (n
7,
14.9%), ability to touch tongue to nose (n
11, 23.4%),
and ability to touch foot to forehead (n
39, 83.0%). Of
the 20 connective tissue features interrogated, 45 of 47
FMD case subjects (95.7%) had 4 features present on
clinical examination (Fig. 2).
The study MRA was performed in 43 subjects able to
undergo the procedure. Multifocal stenosis was ob-
served in 26 subjects, and the lack of observed beading
in the primary arterial territory in the remaining sub-
jects is consistent with the clinical history of surgery,
often with resection of the diseased arterial segment
and end-to-end graft implantation, and/or percutane-
ous intervention with stent implantation, precluding
artery visualization. Intracerebral aneurysm was seen in
6 of 47 subjects. In the multivariable regression, plasma
TGF-2 levels were significantly predictive of the arte-
rial severity score of systemic burden of arterial disease
(Table 4).
TABLE 2. FMD case subjects’ self-reported family history of
vascular and genetic diseases
Disease or condition N %
Abdominal aortic aneurysm 8 17.0
Any aneurysm 15 31.9
Arterial dissection 1 2.1
Hypertension 22 46.8
Ehlers-Danlos syndrome 0 0
FMD diagnosed by a physician 1 2.1
Scoliosis diagnosed by a physician 12 25.5
Stroke 28 59.6
Sudden death 8 17.0
N. number of subjects with a positive family history for the listed
diagnoses.
TABLE 3. Spine magnetic resonance imaging features
Feature N %
Degenerative disc disease at any location in the
spine 45 95.7
Degenerative disc disease noted in cervical spine 39 83.0
Degenerative disc disease noted in thoracic
spine 21 44.7
Degenerative disc disease noted in lumbar spine 39 83.0
Facet changes noted at any location 35 74.5
Facet changes at cervical spine 6 12.8
Facet changes at thoracic spine 5 10.6
Facet changes at lumbar spine 34 72.3
Dural ectasia 20 42.6
Chiari I malformation 3 6.4
Tonsillar ectopia 7 14.9
Scoliosis on magnetic resonance imaging 14 29.8
Spinal stenosis at any location in the spine 31 66.0
Spinal stenosis at cervical spine 22 46.8
Spinal stenosis at thoracic spine 5 10.6
Spinal stenosis at lumbar spine 17 36.2
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TGF- pathway biomarker assays
We analyzed plasma samples from the first 38 FMD case
subjects enrolled and 74 age-, sex-, and BMI-matched
apparently healthy control subjects, matched 1:2 when
possible. Case control identities were blinded to the
researcher performing the assays. Circulating
TGF-1 levels were higher in subjects with FMD
compared to control subjects (8.82.2 vs. 2.50.4
ng/ml, P
0.009). Similarly, plasma samples from a
smaller cohort of 15 FMD case subjects and 16 age-,
sex-, and BMI-matched apparently healthy control
subjects showed increased circulating total TGF-2 in
FMD case subjects (124.27.8 vs. 95.83.6 pg/ml,
P
0.004; Fig. 3A).
Secretion of total TGF-1 and TGF-2 from human
skin fibroblasts was measured in a subset of the 25
subjects who provided dermal biopsy samples, includ-
ing 16 FMD case subjects and 14 age- and sex-matched
apparently healthy control subjects, whose cell lines
provided adequate in vitro cell growth. Significant ele-
vation of secreted TGF-1 (215.232.1 vs. 73.97.5
pg/ml/mg protein, P
0.0009) and TGF-2 (54.61.2
vs. 46.81.2 pg/ml/mg protein, P
0.0001) was seen in
FMD case subjects vs. controls (Fig. 3B). There was a
positive correlation between plasma and secreted levels
of TGF-2 (r
0.55). Intracellular downstream TGF-
pathway biomarkers (pSmad2, pSmad1/5/8, pERK1/2,
and p-p38 MAPK) were analyzed by immunoblot and
showed no significant differences, even when stimu-
lated with TGF-1, TGF-2, or BMP-4 (Fig. 4, TGF-2
results same as TGF-1, data not shown). FACS analysis
for cell cycle suggested excess cellular proliferation in
FMD case subject fibroblasts in vitro (Fig. 5), although
assessment of cellular proliferation in the same cell
lines by BrdU assay showed no statistically significant
difference (P
0.36). Protein expression of TGF- re-
ceptors I and II, collagens I, III, and V, fibronectin, and
decorin was not different between patients with FMD
and control subjects (data not shown).
Inflammatory biomarkers in circulating blood
Plasma levels of MCP-1, TNF-, CRP, SAA, ICAM-1, and
VCAM-1 were all significantly elevated in FMD case
subjects relative to age- and sex-matched apparently
healthy control subjects, while IL-8 was significantly
decreased in FMD case subjects (Table 5). IL-8 secreted
from fibroblasts was not different compared to controls
(data not shown). When comparing FMD samples to
the MFS group, we found alterations in TGF-1, TGF- 
2, MCP-1, SAA, ICAM-1, VCAM-1, and IL-8 that were in
similar direction and magnitude. In addition, TGF-1
levels in FMD were similar to those found in an
independent analysis of circulating TGF-1 in MFS
(26). However, TNF- and CRP, which were elevated in
subjects with FMD, were not significantly different in
individuals with MFS as compared to the healthy con-
trol subjects, indicating a distinct pattern of protein
markers in FMD (Table 5).
Figure 2. Distribution of the number of con-
nective tissue dysplasia features per subject
with FMD. For each FMD case subject, the
number of connective tissue features is shown,
tallying the number of the 20 features summa-
rized in Results: Clinical features.
TABLE 4. MRA characteristics and arterial disease severity scores
Characteristic, in any vessel N %
Aneurysm 30 63.8
Dissection 2 4.3
Beading 26 55.3
Stenosis 30 63.8
Tortuosity 6 12.8
Other vascular abnormality 20 42.6
Not visualized by MRA 14 29.8
Severity score
Score 1: beading,
dissection,
aneurysm, or
stenosis on MRA
Score 2: beading
only
N % N %
0 4 8.5 20 42.6
1 17 36.2 13 27.7
2 13 27.7 11 23.4
3 7 14.9 1 2.1
4 2 4.3 0 0
5 3 6.4 1 2.1
6 0 0 0 0
7 0 0 0 0
Sum 47 47
2 territories 53.2 27.7
TGF-2 plasma: score 1, P 
 0.003; score 2, P 
 0.004.
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DISCUSSION
Recent data have suggested that FMD represents a
systemic vasculopathy, with the finding of a clinical
manifestation of the disease in multiple arterial beds in
at least one-third of patients (20). However, systematic
evaluation for clinical and musculoskeletal features has
not previously been performed. Our results indicate
that FMD is a systemic disease with clinical features that
extend beyond arterial pathology to include low bone
density, joint laxity, and degenerative disease in the
spine. The major clinical manifestations of FMD in our
study are related to the vascular pathology and pain
often related to early onset arthritis and degenerative
joint disease in the spine. Based on the constellation of
findings, consistent with a mild and subclinical connec-
tive tissue dysplasia, we hypothesized that TGF- ex-
pression alterations may drive these findings in patients
with FMD. We tested this hypothesis through assays of
circulating plasma and dermal fibroblasts, and we dem-
onstrated that levels of TGF- isoforms and other
inflammatory cytokines are altered.
The demographics and clinical histories of our sub-
jects closely align with a U.S. registry of 447 patients
with FMD (20) despite differences in study methodol-
ogies. We also are aware of 12 subjects enrolled in our
cohort who are also enrolled in the same U.S. registry.
Similar features included percentage of female sex
(91.5 vs. 91.0%), mean age at presentation (44 vs. 47
yr), prevalence of hypertension (66.0 vs. 72.0% at study
enrollment), headache (53.2 vs. 60.0%), current or
former history of smoking (38.3 vs. 37.2%), and a
history of exogenous hormone use (61.7 vs. 69.6%).
However, in our study, 21.3% of our subjects had
undergone surgical treatment for FMD with histopatho-
logic confirmation, in contrast to 3.3% in the U.S.
registry. A higher proportion of our cohort had expe-
rienced a cerebrovascular event (48.9%) as compared
to the U.S. registry, which noted TIA in 8.7% and stroke
in 6.9% of its participants. This may reflect an ascer-
tainment bias for patients who are more severely af-
fected in being motivated to undertake the travel
requirements for participation at the NIH. Our cohort
did not include any individuals with asymptomatic
disease discovered incidentally, whereas the U.S. regis-
try included 5.6% with no symptoms or signs. In our
study, surveillance MRA imaging of the entire arterial
tree showed that 53.2% of our study subjects had
vascular disease (aneurysm, beading, stenosis, or dissec-
tion) involving 2 arterial beds. Multiple vascular bed
involvement was noted in 26.0–35.3% of patients with
FMD in the U.S. registry who had imaging performed
on additional arterial territories as clinically necessi-
tated. Several caveats to the interpretation of our study
MRA findings include that motion artifact from breath-
ing is generally problematic for abdominal studies,
previously treated arterial beds in cases of prior surgery
or stent implantation could not be assessed, and we
were unable to study every subject in the cohort be-
cause of contraindications to MR and/or gadolinium
contrast administration. These caveats may have led to
underestimating the severity and burden of systemic
disease. Brain MR imaging is less susceptible to motion
artifact, and we found that 12.8% of subjects had an
intracerebral aneurysm. In the U.S. registry, 9 of 76
(11.8%) individuals with imaging data had a cerebral
artery aneurysm, and 16 of 76 (21.1%) had carotid
artery aneurysm, including both extracranial and intra-
cranial internal carotid artery. Overall, the close align-
ment of demographic variables in our study as com-
pared to the U.S. registry indicates that our cohort is a
representative sample of U.S. patients with FMD, but
likely with more severe clinical disease.
Figure 3. Circulating and secreted TGF- in
FMD. A) Elevated levels of total TGF-1 and
-2 in platelet-poor EDTA-plasma from FMD
case subjects vs. age- and sex-matched healthy
controls. Samples were acid-activated prior to
assaying by ELISA. B) Secreted total TGF-1
and -2 from cultured fibroblasts from FMD
case subjects is elevated vs. healthy controls ex
vivo. Samples were acid activated prior to
assaying by ELISA, and secretion data are
normalized to protein concentration.
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While subjects with FMD had findings often associ-
ated with connective tissue dysplasias, including joint
laxity, scoliosis, craniofacial features, and pes planus,
the findings ranged in severity, with most exhibiting
mild and subclinical findings on physical examination.
Unlike individuals with hypermobile EDS, FMD case
subjects in our study had not come to medical attention
due to recurrent dislocations, refractory joint pain, or
multiple joint surgeries. Tissue fragility, hollow organ
rupture, and lack of healing from surgical scars seen in
the vascular form of EDS were not observed. Scoliosis
and pes planus, when seen in the FMD case subjects,
were much less severe than is typically seen in MFS.
Although the severity of the musculoskeletal findings
was mild, the pattern of these features in our FMD case
subjects may be clinically relevant. Features that were
similar to patients with SMAD3 mutations included
degenerative or facet changes on spine MRI and spinal
stenosis, and neck or back pain in our cohort was
common. In addition, extravascular features associated
with Loeys-Dietz syndrome and MFS, including dural
ectasia, tonsillar ectopia, and Chiari 1 malformation,
were observed (27, 28). In the clinical setting, the
diagnosis of genetic syndromes often requires the con-
sideration of multiple clinical features simultaneously,
which may present heterogeneously in individual sub-
jects, thus necessitating the use of scores or multivari-
able criteria to define a syndrome (28). In our study,
while there was heterogeneity in the number of con-
nective tissue features observed in individuals with
FMD, the vast majority (95.7%) showed 4 of the
features that have been associated with other geneti-
cally mediated connective tissue disorders with vascular
abnormalities. The pattern of these features most
closely resembles that of other connective tissue dyspla-
sias with vascular phenotypes, such as Loeys-Dietz syn-
drome, MFS, or ACTA2 mutation syndromes. In terms
of vascular pathology, the vascular lesion observed in
medial fibroplasia-type FMD appears to be closest to
disorders caused by ACTA2 and NF1 mutations, where
aneurysms and stenotic lesions can be found simulta-
neously, rather than primary mutations in TGF- path-
way genes that typically cause aortic aneurysms and
arterial dissections. To ensure that our cohort did not
contain individuals with pathogenic mutations in these
genes, we screened individuals for specific gene disor-
Figure 4. Western blot analysis of TGF- pathway
biomarkers. Whole-cell lysates from FMD case
subject (n
18) and control fibroblasts (n
14)
were probed for canonical pathway markers
pSmad2 and pSmad1/5/8, treated with TGF-1
or BMP-4, respectively, or untreated noncanoni-
cal markers pERK1/2 and p-p38 MAPK. No
significant differences in biomarker levels were
seen between FMD and control fibroblasts. Rep-
resentative blots are shown; however, quantita-
tion graphs include all samples above. Data were
normalized to the loading control.
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ders based on the established clinical criteria for ge-
netic testing. We used sequencing to evaluate the target
genes in case previously unreported mutations in the
same genes caused a milder phenotype overlapping
with FMD in our study. The yield of these analyses was
low, with no pathogenic mutations identified, consis-
tent with prior reports (21).
Environmental factors contributing to the develop-
ment of FMD have been proposed and include smoking
and mechanical risk factors (6). Hypercholesterolemia
was not more prevalent in our patients compared to
population estimates (29). Given the preponderance of
disease in women and prior data suggesting that exog-
enous estrogen use is higher in the FMD patient
population, hormonal factors appear to play a role (30,
31). Our data showed similar trends as prior reports,
with many subjects reporting a history of exogenous
hormone use. Hormonal milieu also affects joint laxity
and may play a role in the musculoskeletal features of
FMD (25, 32). However, loss of bone density and
arthritis are not associated with exogenous estrogen
use.
Our protein marker analyses showed evidence of
systemic inflammation in subjects with FMD compared
to age- and gender-matched healthy controls with ele-
vation of circulating plasma TGF-1, TGF-2, MCP-1,
TNF-, CRP, SAA, ICAM-1, and VCAM-1 (20, 33, 34).
TGF-1 and TGF-2 are members of the TGF super-
family of cytokines that regulate a variety of cellular
functions in the arterial wall that lead to cellular
proliferation, differentiation, modulation of extracellu-
lar matrix production, and ultimately, arterial remod-
eling (35). The finding of TGF- elevation in FMD is
intriguing, given the similarity of the FMD phenotype
to the spectrum of disorders with altered TGF- signal-
ing, particularly the extravascular manifestations we
identified (36–38). MCP-1 mediates vascular inflamma-
tory cell adhesion and contributes to neointimal hyper-
plasia in the setting of arterial injury (39). The finding
of lower circulating IL-8 is surprising, but not unprec-
edented. IL-8 is known to play an important role in
endothelial cell survival, proliferation, and angiogene-
sis (40, 41). In addition, TGF-1 inhibits IL-8 secretion
during active inflammation in the vascular endothe-
lium, (42) consistent with our findings in patients with
FMD. Furthermore, it was recently shown that patients
with vascular EDS similarly have reduced IL-8 and
elevated circulating TGF-1 (43). Though the exact
mechanism behind reduced IL-8 is unknown, a poten-
tial role in aneurysmal disorders is intriguing and
warrants further study. Elevated CRP, SAA, and TNF-
are seen in acquired autoimmune disorders, although
our FMD patients did not present with usual rheuma-
tologic symptoms and signs. These findings suggest a
state of systemic inflammation in FMD, although vascu-
lar lesions have not characteristically shown active
cellular inflammation (6). For comparison purposes,
we evaluated the same markers in a group of individuals
with MFS, a known disorder of TGF- signaling, and we
found a distinct pattern of protein markers in FMD as
compared to MFS. TGF-1 was elevated in both groups,
but individuals with MFS did not have significant dif-
ferences in TNF- or CRP levels as compared to the
healthy controls as was seen in subjects with FMD, an
intriguing difference between these disorders.
Although the underlying molecular defects are un-
known, our protein marker findings in FMD plasma
Figure 5. FACS analysis of cell cycle profiles of dermal
fibroblasts from FMD case samples with corresponding TGF-
data. FACS analysis shows a shift in the cell cycle profiles of
dermal fibroblasts from subjects with FMD compared to
healthy controls, with a lower proportion of cells in quies-
cence (G0/G1 phase).
TABLE 5. Circulating biomarker comparison between FMD and MFS
Marker
FMD, n 
 38 MFS, n 
 20
Control, n 
 74Value P Value P
TGF-1 (ng/ml) 8.8  2.2 0.009 9.2  1.4 0.0001 2.5  0.4
TNF- (pg/ml) 5.76  0.25 	0.0001 5.04  0.30 NS 4.33  0.18
CRP (ng/ml) 2958  701 0.027 2700  747 NS 1264  171
MCP-1 (pg/ml) 256  11 0.001 270  15 0.0004 211  0.7
SAA (ng/ml) 2698  588 0.026 3142  825 0.037 1281  104
ICAM-1 (ng/ml) 231  11 	0.0001 265  27 0.005 179  6
VCAM-1 (ng/ml) 454  37 0.009 542  40 0.0001 347  12
IL-8 (pg/ml) 1.86  0.13 	0.0001 1.98  0.21 	0.0001 3.46  0.18
Values are presented as means  sem. P  0.05 considered significant; NS, not significant.
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and fibroblast secretion suggest a disturbance of ho-
meostasis in the TGF- axis (44) and other pathways
involved in inflammatory signaling. Since access to
vascular tissue through clinical care is limited, we
utilized dermal fibroblasts to study key pathological
features as has been frequently done in the study of
other hereditary disorders of connective tissue with
vascular features (45–47). It is interesting and informa-
tive that the dermal fibroblast lines obtained from a
large number of FMD case subjects in our study reca-
pitulated the phenotype of increased TGF-1 and
TGF-2 expression ex vivo despite removal from their
hormonal and other potentially interacting milieu.
This suggests that an intrinsic genetic abnormality may
contribute to altered TGF- expression. Since expres-
sion of downstream TGF- biomarkers did not show
clear activation patterns, the exact mechanism invoked
by excess extracellular TGF- in FMD is unclear at this
time and suggests possible locus or allelic heterogene-
ity, requiring further study. It is also possible that
increased TGF- expression is not a primary defect
leading to FMD. Rather, there may be altered down-
stream activation or signaling, leading to possible com-
pensatory pathway activation resulting in elevated
TGF-. The finding that TGF-2 levels are associated
with burden of arterial disease suggests that TGF-2
may drive the extent of vascular disease, but this
hypothesis needs to be formally tested, ideally in vascu-
lar tissues and in vivo given the context dependency of
TGF- effects. Fibroblasts obtained in this study have
been donated to the Coriell repository and are available
to the scientific community. Taken together, the results
of our study show a pattern of clinical manifestations
consistent with TGF- alterations as have been observed
in other hereditary vascular disorders, with specific
vascular manifestations that are unique to FMD.
These findings have potential clinical implications.
Our data suggest that an evaluation of degenerative
spine arthritis and bone density may be helpful in
identifying the cause and possible therapies for muscu-
loskeletal symptoms. The yield of genetic testing for
currently known connective tissue dysplasias in the
FMD population is low in the absence of features that
would otherwise indicate specific genetic testing, con-
sistent with another published study (21). Given the
rapid evolution of our understanding of vascular ge-
netic diseases, formal genetic evaluation of patients
with connective tissue features may be helpful to rule
out other potentially overlapping disorders where FMD
can be seen, such as vascular or type IV EDS. Finally,
anecdotal evidence supports the rationale for therapy
for FMD with pharmacologic agents that are known to
decrease vascular TGF- expression; (48) however, it is
premature to make this treatment recommendation
without a clinical trial. Further studies to identify the
underlying molecular defect in FMD will be needed to
clarify these issues.
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